Compare Stocks

Date Range: 

 CureVacHorizon Therapeutics PublicGenmab A/SUCBMERCK Kommanditgesellschaft auf Aktien
SymbolNASDAQ:CVACNASDAQ:HZNPOTCMKTS:GNMSFOTCMKTS:UCBJFOTCMKTS:MKGAF
Price Information
Current Price$105.79$86.24$365.30$98.00$176.00
52 Week RangeHoldBuyBuyBuyN/A
MarketRank™
Overall Score0.72.80.61.00.5
Analysis Score1.24.50.00.00.0
Community Score2.33.31.92.32.3
Dividend Score0.00.00.00.00.0
Ownership Score0.01.70.00.00.0
Earnings & Valuation Score0.04.41.32.50.0
Analyst Ratings
Consensus RecommendationHoldBuyBuyBuyN/A
Consensus Price Target$58.33$111.36N/AN/AN/A
% Upside from Price Target-44.86% downside29.13% upsideN/AN/AN/A
Trade Information
Market Cap$19.77 billion$19.38 billion$22.54 billion$19.06 billion$22.75 billion
BetaN/A1.150.830.560.7
Average Volume974,3361,841,8751,242412456
Sales & Book Value
Annual RevenueN/A$1.30 billion$804.57 million$5.50 billion$18.09 billion
Price / SalesN/A14.9128.013.461.26
CashflowN/A$3.88 per share$4.77 per share$5.13 per share$37.45 per share
Price / CashN/A22.2276.6419.094.70
Book ValueN/A$11.67 per share$34.13 per share$40.36 per share$155.24 per share
Price / BookN/A7.3910.702.431.13
Profitability
Net IncomeN/A$573.02 million$324.68 million$887.04 million$1.48 billion
EPSN/A$1.94N/A$5.82N/A
Trailing P/E Ratio0.0023.565.1916.840.00
Forward P/E RatioN/A20.0614.24
P/E GrowthN/A0.59N/AN/AN/A
Net MarginsN/A43.55%51.02%N/A10.92%
Return on Equity (ROE)N/A25.66%34.38%N/A14.29%
Return on Assets (ROA)N/A14.19%30.65%N/A5.90%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A0.26%N/AN/AN/A
Current RatioN/A3.49%8.64%N/A1.06%
Quick RatioN/A3.39%8.64%N/A0.70%
Ownership Information
Institutional Ownership Percentage4.32%88.59%0.04%N/AN/A
Insider Ownership PercentageN/A4.30%N/AN/AN/A
Miscellaneous
Employees5001,3957817,82058,127
Shares Outstanding186.91 million224.77 million61.69 million194.51 million129.24 million
Next Earnings DateN/A8/4/2021 (Estimated)8/11/2021 (Estimated)5/27/2021 (Estimated)5/13/2021 (Estimated)
OptionableNot OptionableOptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
MERCK Kommanditgesellschaft auf Aktien (OTCMKTS:MKGAF) Short Interest Down 31.6% in AprilMERCK Kommanditgesellschaft auf Aktien (OTCMKTS:MKGAF) Short Interest Down 31.6% in April
americanbankingnews.com - May 1 at 4:54 PM
MERCK Kommanditgesellschaft auf Aktien (OTCMKTS:MKGAF) Short Interest Up 27.8% in MarchMERCK Kommanditgesellschaft auf Aktien (OTCMKTS:MKGAF) Short Interest Up 27.8% in March
americanbankingnews.com - April 19 at 11:20 AM
Global DNA Microarray Market to Hit USD 6196.7 Mn By 2028 | CAGR Of 10.1%Global DNA Microarray Market to Hit USD 6196.7 Mn By 2028 | CAGR Of 10.1%
northwestgeorgianews.com - April 5 at 8:06 AM
Germanys Merck in fresh investment to make bioreactor gear in FranceGermany's Merck in fresh investment to make bioreactor gear in France
finance.yahoo.com - March 17 at 2:59 PM
EuropeFX Adds Pharma Stocks To Asset ListEuropeFX Adds Pharma Stocks To Asset List
prweb.com - September 25 at 10:35 AM
Merck KGaA says it has overcome production shortages in vaccine materialsMerck KGaA says it has overcome production shortages in vaccine materials
financialpost.com - September 16 at 12:56 PM
EMD Serono Advances Oncology Portfolio and Pipeline with New and Long-term Data in Multiple Cancers at ESMO 2020EMD Serono Advances Oncology Portfolio and Pipeline with New and Long-term Data in Multiple Cancers at ESMO 2020
markets.businessinsider.com - September 13 at 6:44 PM
Gileads remdesivir to be tested with Merck KGaAs interferon vs. COVID by NIHGilead's remdesivir to be tested with Merck KGaA's interferon vs. COVID by NIH
feeds.marketwatch.com - August 7 at 11:14 AM
EU secures potential COVID-19 drugs from Roche, Germany’s Merck – sourceEU secures potential COVID-19 drugs from Roche, Germany’s Merck – source
business.financialpost.com - July 8 at 2:20 PM
Temprian Therapeutics Finalist in Nature Merck Spinoff 2020 CompetitionTemprian Therapeutics Finalist in Nature Merck Spinoff 2020 Competition
www.prweb.com - July 2 at 12:50 PM
Rebif® U.S. Label Now Includes Pregnancy Outcomes and Lactation Information to Help Inform Treatment Decisions for Women with MSRebif® U.S. Label Now Includes Pregnancy Outcomes and Lactation Information to Help Inform Treatment Decisions for Women with MS
www.prnewswire.com - May 27 at 5:31 PM
New Late-Breaking Data at EAN Indicate Evobrutinib is the First BTK Inhibitor to Report Efficacy and Safety in MS Over 108 WeeksNew Late-Breaking Data at EAN Indicate Evobrutinib is the First BTK Inhibitor to Report Efficacy and Safety in MS Over 108 Weeks
markets.businessinsider.com - May 23 at 2:36 AM
A Fundação Merck anuncia os prémios de jornalismo Fique em Casa para países latino-americanosA Fundação Merck anuncia os prémios de jornalismo 'Fique em Casa' para países latino-americanos
prnmedia.prnewswire.com - May 21 at 3:58 AM
Genome & Company reçoit lautorisation DNR de la FDA pour le GEN-001, son premier microbiome thérapeutique anti-cancerGenome & Company reçoit l'autorisation DNR de la FDA pour le GEN-001, son premier microbiome thérapeutique anti-cancer
www.prnewswire.com - April 21 at 3:46 AM
ERBITUX® Approved for First-line Use in China in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)ERBITUX® Approved for First-line Use in China in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)
finance.yahoo.com - March 2 at 3:33 AM
Does MERCK Kommanditgesellschaft auf Aktien's (ETR:MRK) CEO Pay Matter?Does MERCK Kommanditgesellschaft auf Aktien's (ETR:MRK) CEO Pay Matter?
finance.yahoo.com - January 22 at 3:56 AM
Genome & Company announces a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany and PfizerGenome & Company announces a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer
www.prnewswire.com - January 13 at 8:43 PM
Merck KGaA to reconsider selling allergy business - BloombergMerck KGaA to reconsider selling allergy business - Bloomberg
seekingalpha.com - January 9 at 3:34 PM
Ping An Good Doctor and Merck KGaA, Darmstadt, Germany Form Strategic Collaboration to Advance Intelligent Healthcare in ChinaPing An Good Doctor and Merck KGaA, Darmstadt, Germany Form Strategic Collaboration to Advance Intelligent Healthcare in China
www.prnewswire.com - December 4 at 4:54 AM
Isofol Receives Positive Feedback From PMDA in Japan, Expanding Ongoing Global Pivotal Phase 3 AGENT Trial in First Line Metastatic Colorectal CancerIsofol Receives Positive Feedback From PMDA in Japan, Expanding Ongoing Global Pivotal Phase 3 AGENT Trial in First Line Metastatic Colorectal Cancer
www.prnewswire.com - October 18 at 5:19 AM
Versum Materials Announces China Antitrust Clearance of Merger with Merck KGaA, Darmstadt, Germany; Announces Expected Closing DateVersum Materials Announces China Antitrust Clearance of Merger with Merck KGaA, Darmstadt, Germany; Announces Expected Closing Date
www.businesswire.com - October 1 at 10:52 AM
Vaccinex Presents Updated Interim Data from a Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer in Podium and Poster Presentations at the Fifth International Cancer lmmunotherapy Conference in Paris, FranceVaccinex Presents Updated Interim Data from a Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer in Podium and Poster Presentations at the Fifth International Cancer lmmunotherapy Conference in Paris, France
www.benzinga.com - September 27 at 6:36 AM
New Data at ESMO 2019 for Merck KGaA, Darmstadt, Germany, Highlight Focused Clinical Development and Commitment to Patient CareNew Data at ESMO 2019 for Merck KGaA, Darmstadt, Germany, Highlight Focused Clinical Development and Commitment to Patient Care
markets.businessinsider.com - September 23 at 2:12 AM
Merck KGaAs Q2 profit bolstered by drug milestone paymentsMerck KGaA's Q2 profit bolstered by drug milestone payments
feeds.reuters.com - August 8 at 3:51 AM
UPDATE 1-Merck KGaAs profit bolstered by lab supplies, drug milestone paymentsUPDATE 1-Merck KGaA's profit bolstered by lab supplies, drug milestone payments
feeds.reuters.com - August 8 at 3:51 AM
DateCompanyBrokerageAction
5/3/2021CureVacGuggenheimInitiated Coverage
4/26/2021CureVacCredit Suisse GroupInitiated Coverage
11/17/2020CureVacBerenberg BankReiterated Rating
9/8/2020CureVacBank of AmericaInitiated Coverage
9/8/2020CureVacJefferies Financial GroupInitiated Coverage
3/29/2021Horizon Therapeutics PublicMorgan StanleyReiterated Rating
3/24/2021Horizon Therapeutics PublicCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellReiterated Rating
3/23/2021Horizon Therapeutics PublicStifel NicolausBoost Price Target
3/17/2021Horizon Therapeutics PublicWolfe ResearchInitiated Coverage
11/3/2020Horizon Therapeutics PublicBMO Capital MarketsBoost Price Target
9/9/2020Horizon Therapeutics PublicJPMorgan Chase & Co.Initiated Coverage
7/22/2020Horizon Therapeutics PublicPiper SandlerBoost Price Target
11/25/2020Genmab A/SUBS GroupReiterated Rating
8/13/2020Genmab A/SBarclaysReiterated Rating
10/1/2018Genmab A/SHC WainwrightReiterated Rating
(Data available from 5/11/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.